Skip to main content

InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports ‘Promising’ Results in Preclinical Studies Evaluating Drug Candidate for Alzheimer’s Treatment

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, reported on the results of preclinical studies evaluating its drug candidate TGR-63 as a treatment for Alzheimer’s disease. According to the report, the data showed enhanced memory function, including memory acquisition, consolidation and retrieval, in an Alzheimer’s mouse model. The preclinical studies included the use of two behavioral tests: the Novel Object Recognition (“NOR”) Test and the Morris Water Maze (“MWM”); APP/PS1 genetically modified Alzheimer’s mice were used in the evaluations. The company noted that its TGR-63 is a therapeutic candidate designed to disrupt the structure of the amyloid-β (Aβ) peptide in an attempt to reduce signs of cognitive impairment, such such as memory loss and disrupted learning ability. “These results underscore the efficacy of TGR-63 in enhancing spatial memory function in an Alzheimer’s disease model, offering promising implications for potential therapeutic interventions in Alzheimer’s and related neurodegenerative conditions,” said IGC Pharma CEO Ram Mukunda in the press release. “The improvements in memory acquisition, consolidation, spatial memory formation, and retrieval highlight its potential in addressing cognitive impairment in Alzheimer’s disease. We are optimistic about TGR-63’s potential and anticipate advancing it towards a phase 1 trial, enriching our clinical portfolio.”

To view the full press release, visit https://ibn.fm/wwPMN

About IGC Pharma

IGC Pharma is pursuing innovative solutions to fight Alzheimer’s disease and related challenges. The company’s portfolio comprises five assets, all with a singular mission: to transform the landscape of Alzheimer’s treatment. IGC-AD1 and LMP target neuroinflammation, Aβ plaques and neurofibrillary tangles. IGC-AD1 is currently in a phase 2b clinical trial for agitation in dementia due to Alzheimer’s. TGR-63 targets Aβ plaque to disrupt the progression of Alzheimer’s disease. IGC-M3 targets the inhibition of Aβ plaque aggregation with the potential to create a profound impact on early-stage Alzheimer’s. IGC-1C targets tau and neurofibrillary tangles as a forward-thinking approach to Alzheimer’s therapy. In parallel, IGC Pharma is at the forefront of generative AI development, with projects including clinical trials, early detection of Alzheimer’s and drug interactions with cannabinoids. For more information, visit the company’s website at www.IGCInc.us.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.